Management of Myocardial Infarction in Children with Giant Coronary Artery Aneurysms after Kawasaki Disease

J Pediatr. 2020 Jun:221:230-234. doi: 10.1016/j.jpeds.2020.02.033. Epub 2020 Apr 17.

Authors

Jane C Burns¹, Howaida El-Said², Adriana H Tremoulet², Kevin Friedman³, John B Gordon⁴, Jane W Newburger³

Affiliations

¹ Department of Pediatrics, University of California San Diego School of Medicine, and Rady Children's Hospital San Diego, San Diego, CA. Electronic address: jcburns@ucsd.edu.
² Department of Pediatrics, University of California San Diego School of Medicine, and Rady Children's Hospital San Diego, San Diego, CA.
³ Department of Cardiology, Boston Children's Hospital, Boston, MA; Department of Pediatrics, Harvard Medical School, Boston, MA.
⁴ San Diego Cardiac Center and Sharp Memorial Hospital, San Diego, CA.

PMID: 32312552
DOI: 10.1016/j.jpeds.2020.02.033

No abstract available

Keywords: anticoagulation; ischemia; pediatrics; thrombosis; vasculitis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anticoagulants / therapeutic use
Antithrombin III / analysis
Antithrombin III / therapeutic use
Antithrombins / therapeutic use
Biomarkers / blood
Child
Clinical Decision-Making
Clinical Protocols
Coronary Aneurysm / etiology
Coronary Aneurysm / therapy*
Fibrinogen / analysis
Fibrinolytic Agents / therapeutic use
Heparin / therapeutic use
Humans
Mucocutaneous Lymph Node Syndrome / complications*
Myocardial Infarction / etiology
Myocardial Infarction / therapy*
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors / therapeutic use
Prognosis
Tissue Plasminogen Activator / therapeutic use

Substances

Anticoagulants
Antithrombins
Biomarkers
Fibrinolytic Agents
Platelet Aggregation Inhibitors
Antithrombin III
Fibrinogen
Heparin
Tissue Plasminogen Activator